As gener­ic com­pe­ti­tion stut­ter sales of top on­col­o­gy drugs, Roche se­cures speedy re­view for pair of ex­per­i­men­tal can­cer of­fer­ings

As drug de­vel­op­ers seek ways to ex­pand ther­a­peu­tic ap­pli­ca­tions and over­come the hur­dles seen with the first gen­er­a­tion of an­ti­body drug con­ju­gates (AD­Cs), Roche is cap­i­tal­iz­ing on its tro­jan horse ADC — pow­ered by Seat­tle Ge­net­ics’ tech­nol­o­gy — as gener­ics eat in­to the sales of its tri­fec­ta of top can­cer drugs. On Tues­day, the Swiss drug­mak­er said its an­ti-CD79b ADC — po­latuzum­ab ve­dotin — had won the FDA’s pri­or­i­ty re­view for use in pa­tients with re­lapsed or re­frac­to­ry dif­fuse large B-cell lym­phoma (DL­B­CL), a field that is with­in the clutch of CAR-T ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER